Find the latest gastric cancer research updates and case studies, such as a 72-year-old man with previously treated metastatic gastric cancer who receives ramucirumab/paclitaxel, in this video from Research To Practice.
Do you know risk factors for gastric cancer? Using genomic technologies, a study published in Cell Press looks into the effects of having Helicobacter pylori infections and intestinal metaplasia on gastric cancer occurrence and progression.
You can be part of advancing critical research needed for a cure. Ask your physician how you can contribute to our Gastric Cancer Registry at the Stanford Cancer Institute.
You can make an impact on the lives of someone affected by cancer – and help us continue providing support to our community. Visit http://bit.ly/2mEBplx, click our logo and share. For every share, Merck will donate $5 to our community.
Athenex, Inc. has released encouraging results in their recently completed Phase 1 clinical trial for Oraxol (oral paclitaxel) plus CYRAMZA® (ramucirumab) in gastric cancer patients who had failed previous chemotherapy treatments. Oraxol is an oral formulation of paclitaxel, a commonly used chemotherapy, combined with HM30181A (a novel P-gp inhibitor).
Meet our newest Board Member, Arlene Weintraub Moskowitz, an award-winning journalist and author with 20 years of experience writing about healthcare, pharmaceuticals, and biotech. Arlene is committed to helping advance awareness and research for gastric cancer after losing her sister, a mother of four, to the disease earlier this decade. We’re lucky to have her expertise on board. Read her full bio here. http://bit.ly/2BAKxxi
Although it's a long way from being a marketable device, researchers at Johns Hopkins Medicine Kimmel Cancer Center have developed a blood test (CancerSEEK) that screens and identified the location of certain cancer types, including gastric cancer.
You can help someone living with cancer with every share of Your Cancer Game Plan. It will also help us provide continued support and guidance to our community. Visit http://bit.ly/2mEBplx & click on our logo to start sharing.
Who is at risk and what can be done to prevent and treat gastric cancer?
Data shared at American Society of Clinical Oncology's Gastrointestinal Cancers Symposium also included research that found hyperthermic intraperitoneal chemotherapy (HIPEC), which delivers chemotherapy directly to cancer cells in the abdomen, increases survival for gastric cancer patients with peritoneal metastasis.
Earlier detection for gastric cancer is becoming possible and attention is finally on our younger patients, whose incidence is increased. Read more in the American Society of Clinical Oncology roundup.